Terns Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, will present preclinical data on their novel allosteric BCR-ABL inhibitor, TERN-701, at the 30th European Hematology Association Congress (EHA25) in Milan, Italy. The event will take place from June 12-15, 2025. The presentation, scheduled for June 13, 2025, will highlight the potency of TERN-701 against various resistance mutations in chronic myeloid leukemia $(CML.UK)$, showcasing its potential clinical benefits over existing therapies.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。